Targeted Disease(s):
Lung Cancer
Purpose of Study:
The primary objective of the dose escalation (phase 1) part of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of REGN5093 for determination of the maximum tolerated dose (MTD) and/or definition of the recommended phase 2 dose (RP2D) of REGN5093 in patients with MET-altered Non-small cell lung cancer(NSCLC).The primary objective of the dose expansion (phase 2) part of the study is to assess preliminary anti-tumor activity of REGN5093 as measured by the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Study Dates:
January 17, 2020 - February 15, 2024
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
Regeneron Pharmacuticals
Sponsors:
Regeneron Pharmaceuticals
Contact:
Name: Massive Bio
Phone: 844-627-7246
Email: [email protected]
ClinicalTrails.gov Identifier:
NCT04077099
